183 related articles for article (PubMed ID: 25298195)
1. Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin.
Takahashi A; Fukusumi Y; Yamazaki M; Kayaba M; Kitazawa Y; Tomita M; Kawachi H
J Nephrol; 2014 Dec; 27(6):627-34. PubMed ID: 25298195
[TBL] [Abstract][Full Text] [Related]
2. Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome.
Fukuda A; Fujimoto S; Iwatsubo S; Kawachi H; Kitamura K
Nephrology (Carlton); 2010 Apr; 15(3):321-6. PubMed ID: 20470301
[TBL] [Abstract][Full Text] [Related]
3. Key molecular events in puromycin aminonucleoside nephrosis rats.
Guan N; Ding J; Deng J; Zhang J; Yang J
Pathol Int; 2004 Sep; 54(9):703-11. PubMed ID: 15363039
[TBL] [Abstract][Full Text] [Related]
4. Dissociation of NEPH1 from nephrin is involved in development of a rat model of focal segmental glomerulosclerosis.
Otaki Y; Miyauchi N; Higa M; Takada A; Kuroda T; Gejyo F; Shimizu F; Kawachi H
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1376-87. PubMed ID: 18715943
[TBL] [Abstract][Full Text] [Related]
5. Slit diaphragm dysfunction in proteinuric states: identification of novel therapeutic targets for nephrotic syndrome.
Kawachi H; Suzuki K; Miyauchi N; Hashimoto T; Otaki Y; Shimizu F
Clin Exp Nephrol; 2009 Aug; 13(4):275-280. PubMed ID: 19266252
[TBL] [Abstract][Full Text] [Related]
6. Neph1 is reduced in primary focal segmental glomerulosclerosis, minimal change nephrotic syndrome, and corresponding experimental animal models of adriamycin-induced nephropathy and puromycin aminonucleoside nephrosis.
Hulkko J; Patrakka J; Lal M; Tryggvason K; Hultenby K; Wernerson A
Nephron Extra; 2014 Sep; 4(3):146-54. PubMed ID: 25404935
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between podocyte molecule's distribution and expression, foot process morphology and proteinuria].
Guan N; Deng JH; Ding J; Zhang JJ; Yang JY
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):139-44. PubMed ID: 15100730
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
[TBL] [Abstract][Full Text] [Related]
9. Nephrin and podocin expression around the onset of puromycin aminonucleoside nephrosis.
Hosoyamada M; Yan K; Nishibori Y; Takiue Y; Kudo A; Kawakami H; Shibasaki T; Endou H
J Pharmacol Sci; 2005 Feb; 97(2):234-41. PubMed ID: 15684566
[TBL] [Abstract][Full Text] [Related]
10. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.
Whaley-Connell A; Nistala R; Habibi J; Hayden MR; Schneider RI; Johnson MS; Tilmon R; Rehmer N; Ferrario CM; Sowers JR
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F655-61. PubMed ID: 20007350
[TBL] [Abstract][Full Text] [Related]
11. Multi-glycoside of Tripterygium wilfordii Hook. f. reduces proteinuria through improving podocyte slit diaphragm dysfunction in anti-Thy1.1 glomerulonephritis.
Wan YG; Sun W; Zhen YJ; Che XY; Pu HP; Wang Y; Li M; Ruan JG; Yan QJ
J Ethnopharmacol; 2011 Jun; 136(2):322-33. PubMed ID: 21570456
[TBL] [Abstract][Full Text] [Related]
12. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
Nakhoul F; Ramadan R; Khankin E; Yaccob A; Kositch Z; Lewin M; Assady S; Abassi Z
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Hayashi K; Sasamura H; Nakamura M; Sakamaki Y; Azegami T; Oguchi H; Tokuyama H; Wakino S; Hayashi K; Itoh H
Kidney Int; 2015 Oct; 88(4):745-53. PubMed ID: 26108068
[TBL] [Abstract][Full Text] [Related]
14. [Differential expressions of miRNAs in kidney in puromycin aminonucleoside nephropathy model and intervened effects of Leizhi capsule].
Sun W; Li CQ; Chen JH; Shao JD; Zhou D; Zhang L; Gao K
Zhongguo Zhong Yao Za Zhi; 2013 Jan; 38(1):81-90. PubMed ID: 23596882
[TBL] [Abstract][Full Text] [Related]
15. Possible role for glomerular-derived angiotensinogen in nephrotic syndrome.
Yamazaki M; Fukusumi Y; Kayaba M; Kitazawa Y; Takamura S; Narita I; Kawachi H
J Renin Angiotensin Aldosterone Syst; 2016 Oct; 17(4):. PubMed ID: 27932705
[TBL] [Abstract][Full Text] [Related]
16. Cloning of rat homologue of podocin: expression in proteinuric states and in developing glomeruli.
Kawachi H; Koike H; Kurihara H; Sakai T; Shimizu F
J Am Soc Nephrol; 2003 Jan; 14(1):46-56. PubMed ID: 12506137
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II induces nephrin dephosphorylation and podocyte injury: role of caveolin-1.
Ren Z; Liang W; Chen C; Yang H; Singhal PC; Ding G
Cell Signal; 2012 Feb; 24(2):443-450. PubMed ID: 21982880
[TBL] [Abstract][Full Text] [Related]
18. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.
Okada T; Sakaguchi T; Hatamura I; Saji F; Negi S; Otani H; Muragaki Y; Kawachi H; Shigematsu T
Clin Exp Nephrol; 2009 Oct; 13(5):438-446. PubMed ID: 19452240
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression.
Mii A; Shimizu A; Masuda Y; Ishizaki M; Kawachi H; Iino Y; Katayama Y; Fukuda Y
Lab Invest; 2009 Feb; 89(2):164-77. PubMed ID: 19139720
[TBL] [Abstract][Full Text] [Related]
20. Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-induced nephropathy.
Wang N; Wei RB; Li P; Li QP; Yang X; Yang Y; Huang MJ; Wang R; Yin Z; Lv Y; Chen XM
J Renin Angiotensin Aldosterone Syst; 2016; 17(2):1470320316646884. PubMed ID: 27169889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
